Catumaxomab

Catumaxomab
Monoclonal antibody
Type	Trifunctional antibody
Source	Rat/mouse hybrid
Target	EpCAM, CD3
Clinical data
Trade names	Removab, others
AHFS/Drugs.com	International Drug Names
Routes of; administration	intraperitoneal infusion
ATC code	L01FX03 (WHO) ;
Legal status
Legal status	EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	509077-98-9 ;
DrugBank	DB06607 ;
ChemSpider	none;
UNII	M2HPV837HO;
	(what is this?) (verify)

Catumaxomab, sold under the brand name Removab among others, is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).^[3]

^ Cite error: The named reference Korjuny EPAR was invoked but never defined (see the help page).
^ Cite error: The named reference Korjuny PI was invoked but never defined (see the help page).
^ Linke R, Klein A, Seimetz D (2010). "Catumaxomab: clinical development and future directions". mAbs. 2 (2): 129–36. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.

[Korjuny_EPAR-1] Cite error: The named reference Korjuny EPAR was invoked but never defined (see the help page).

[Korjuny_PI-2] Cite error: The named reference Korjuny PI was invoked but never defined (see the help page).

[3] Linke R, Klein A, Seimetz D (2010). "Catumaxomab: clinical development and future directions". mAbs. 2 (2): 129–36. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.

[1]

[2]

[3]